BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BC Innovations | Jun 13, 2019
Product Development

Why BioMarin took gene therapy manufacturing into its own hands

As gene therapy companies fight for space at contract manufacturers, BioMarin has leveraged its expertise in biologics to design its own capabilities for manufacturing gene therapies and gain control of the process -- a move...
BC Week In Review | Oct 26, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
BC Extra | Oct 23, 2018
Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Jan 27, 2018
Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
BioCentury | Jan 13, 2018
Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
BioCentury | May 20, 2017
Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
BC Extra | May 15, 2017
Company News

Orphan drug giant Termeer passes away

Henri Termeer, the former chairman, president and CEO of Genzyme Corp. and one of the handful of individuals who personified the biotech industry in its early decades, passed away May 12 at age 71. Termeer...
Items per page:
1 - 10 of 356